MEXICO CITY--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a healthcare company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to reduce the use of antibiotics by preventing or treating infections including those caused by bacteria and viruses, announced that its manufacturing facility in Mexico is working around the clock to meet the sudden product demand for Microdacyn™, a broad-spectrum antiseptic and sterilant approved by the Mexican Ministry of Health. Microdacyn has not been reviewed for similar indications by U.S. or European regulatory authorities nor has any regulatory body approved this technology for a specific swine flu indication.
